FDA: Eczema drug labels note cancer risk
Improved labeling addresses concern of possible cancer risk from Elidel Cream and Protopic Ointment.

NEW YORK (CNNMoney.com) - The FDA announced improved labeling for two topical eczema drugs, Elidel Cream and Protopic Ointment, which have been linked to rare reports of cancer.

The labeling will be updated with a boxed warning about potential cancer risk.

'Me-too' drugs rake in sales
Copycats like Lipitor can make billions, or fail like Vioxx and Bextra. (Full story)

"We are taking steps to ensure that healthcare providers and patients are aware of the possible long-term risks of these products so that they will be used appropriately," said Dr. Steven Galson, Director of the FDA's Center for Drug Evaluation and Research.

Eczema is a common skin disorder, affecting as much as 15 percent of the childhood population.

The drugs had been of concern since the FDA issued a Public Health Advisory in March 2005 advising physicians about a potential cancer risk. A definitive causal link between the eczema drugs and cancer has not been established, although rare reports of skin cancer and lymphoma.


3pm slump? Wondering how to get more energy? Read the full story here.

For all the latest headlines in News, click hereTop of page

Follow the news that matters to you. Create your own alert to be notified on topics you're interested in.

Or, visit Popular Alerts for suggestions.
Manage alerts | What is this?